Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00432458 · OUTCOME

Time to Subsequent Treatment

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma · Source last updated 2012-07-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
years
Interval / dispersion
95% Confidence Interval
Time frame
time from end of treatment to subsequent treatment (up to 5 years)

What was measured

Time to subsequent treatment (TTS) was defined as time from end of active (protocol) treatment to the start of subsequent treatment for participants with progressive disease. The median TTS with 95% CI was estimated using the Kaplan Meier method

Analysis population: This data was not (and will never be) analyzed as it was not submitted consistently across all participants.

Groups in this outcome

Arm I: Thal/ZLD

Thalidomide (Thal) + Zolendronic acid (ZLD)

Arm II: ZLD

Zoledronic acid (ZLD)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I: Thal/ZLD0
Arm II: ZLD0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Time to subsequent treatment (TTS) was defined as time from end of active (protocol) treatment to the start of subsequent treatment for participants with progressive disease. The median TTS with 95% CI was estimated using the Kaplan Meier method
dispersion Type
95% Confidence Interval
groups
  1. description
    Thalidomide (Thal) + Zolendronic acid (ZLD)
    id
    OG000
    title
    Arm I: Thal/ZLD
  2. description
    Zoledronic acid (ZLD)
    id
    OG001
    title
    Arm II: ZLD
param Type
MEDIAN
population Description
This data was not (and will never be) analyzed as it was not submitted consistently across all participants.
reporting Status
POSTED
time Frame
time from end of treatment to subsequent treatment (up to 5 years)
title
Time to Subsequent Treatment
type
SECONDARY
unit Of Measure
years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice